Building an Efficient Production System and Ensuring a Stable Supply of High-Quality Pharmaceuticals
First written in FY2016. 5 of 10 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「September 2025 An additional formulation plant was built on the head office premises.」
The plan to expand the formulation plant through the previous fiscal year was completed, and the addition of a formulation plant on the head office premises in September 2025 was reported. - 2026-05-11AdvancedEarnings presentation materials
「Property, plant and equipment: Increase in buildings, structures and production equipment due to construction of a new plant in the pharmaceutical business」
The increase in buildings, structures and production equipment associated with construction of a new plant was disclosed, indicating progress in investment in production capacity. - FY2025AdvancedAnnual report
「Matsumoto Plant Production equipment 3,056 1,564 Internal funds September 2023 August 2025 Expansion Shiojiri Plant Production equipment 1,404 390 Internal funds September 2023 August 2025 Expansion」
The production equipment expansion plan for the Matsumoto and Shiojiri plants specified completion in August 2025, and amounts already paid were also recorded. - FY2024AdvancedAnnual report
「Matsumoto Plant Production equipment 3,016 147 Internal funds September 2023 October 2025 Expansion Shiojiri Plant Production equipment 1,376 225 Internal funds September 2023 October 2025 Expansion」
The plan to expand production equipment at the Matsumoto and Shiojiri plants, with a total investment of ¥4,392 million and completion scheduled for October 2025, has been defined in detail. - FY2022RestatedAnnual report
「We will comply with laws and regulations, take measures to prevent the spread of COVID-19, and work to ensure a stable supply of high-quality products and pharmaceuticals and improve productivity.」
Compliance with laws and regulations, prevention of the spread of infection, a stable supply of high-quality products and pharmaceuticals, and productivity improvement were reconfirmed as priorities for strengthening the management foundation. - FY2020RestatedAnnual report
「④ Strengthening the management foundation to respond to changes in the business environment We will comply with laws and regulations and work to ensure a stable supply of high-quality products and pharmaceuticals and improve productivity.」
Compliance with laws and regulations, a stable supply of high-quality products and pharmaceuticals, and productivity improvement were reconfirmed as priorities for strengthening the management foundation. - FY2019RestatedAnnual report
「We will work to stabilize production of new product lines at an early stage, improve the efficiency of manufacturing and logistics costs, and promote a stable supply of safe, reliable, high-quality pharmaceuticals that reflects customer needs.」
Stable production of new products, manufacturing and logistics cost efficiency, and a stable supply of high-quality pharmaceuticals remain priorities. - FY2018RestatedAnnual report
「We will work to stabilize production of new product lines at an early stage, improve the efficiency of manufacturing and logistics costs, and promote a stable supply of safe, reliable, high-quality pharmaceuticals that reflects customer needs.」
Stable production of new products, manufacturing and logistics cost efficiency, and a stable supply of high-quality pharmaceuticals remain priorities. - FY2017RestatedAnnual report
「We will work to stabilize production of new product lines at an early stage, improve the efficiency of manufacturing and logistics costs, and promote a stable supply of safe, reliable, high-quality pharmaceuticals that reflects customer needs.」
Stable production of new products, manufacturing and logistics cost efficiency, and a stable supply of high-quality pharmaceuticals remain priorities. - FY2016First statedAnnual report
「We will improve the efficiency of pharmaceutical production and logistics costs, accelerate the establishment of stable, ongoing production of new drugs and product lines, and promote a stable supply of safe, reliable, high-quality pharmaceuticals that reflects customer needs.」
Production and logistics cost efficiency, stable production, and a safe, reliable supply are presented as integrated priorities.